IOL CHEMICALS & PHARMACEUTICALS LTD.

IOL Chemicals & Pharmaceuticals Ltd announced significant expansion initiatives. The company is increasing its Ibuprofen manufacturing capacity by 6,000 MT per annum to a total of 18,000 MT, with a ₹350 Crore investment funded by internal accruals. Additionally, it is diversifying into Contract Development and Manufacturing Organisation (CDMO) for pharmaceutical formulations with a new facility costing ₹110 Crore, also funded internally. This new CDMO business, targeting European customers, has received GMP certification and is expected to commercialize in Q3 FY27. The company is also establishing a dedicated specialty chemicals manufacturing facility under a long-term tolling arrangement for a global chemical company, involving a ₹35 Crore investment, expected to commercialize in Q3 FY27.

IOL Chemicals & Pharmaceuticals Ltd has communicated to its shareholders regarding the 39th Annual General Meeting (AGM) scheduled for September 2, 2026. The AGM will be held via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company is distributing the AGM Notice and the Annual Report for the Financial Year 2025-26 exclusively through electronic mode to shareholders whose email addresses are registered. For shareholders with un-registered email addresses, a letter providing a weblink to access the integrated annual report has been sent. The report and notice are also available on the websites of BSE, NSE, and CDSL. Shareholders are advised to update their email addresses with the RTA or DPs as applicable.

IOL Chemicals & Pharmaceuticals Ltd. announced its unaudited financial results for the quarter ended June 30, 2026, reporting a record quarterly performance with the highest-ever revenue of ₹756.3 Cr, a 37.1% year-on-year increase. EBITDA grew by 60.7% to ₹111.7 Cr, and PAT surged by 89.9% to ₹64.5 Cr. The Pharmaceuticals segment was a key growth driver, with revenue up 43% YoY and EBIT up 72% YoY. The Chemicals business also saw significant growth, with revenue up 29% YoY and EBIT up 193% YoY. Exports contributed 28.5% of revenue. The company also received NMPA approval for its Clopidogrel API in China.

IOL Chemicals & Pharmaceuticals Ltd announced its Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on August 10, 2026. The Limited Review Reports from the Statutory Auditors, Ashwani & Associates, were also submitted and confirmed an unmodified conclusion. The financial results are available on the company's website.

IOL Chemicals and Pharmaceuticals reported consolidated revenue of ₹756.26 Cr for Q1 FY27, up 37.1% YoY from ₹551.69 Cr and 22.1% QoQ from ₹619.45 Cr. Consolidated PAT came in at ₹64.40 Cr, up 89.8% YoY from ₹33.93 Cr and 21.1% QoQ from ₹53.16 Cr, with EPS at ₹2.19 versus ₹1.16 a year ago. There were no exceptional items in the current or comparison quarters, so the growth is entirely operating in nature — unlike FY26's full-year print, which carried an ₹11.21 Cr one-off charge. Operating margin expanded to 13.69% from 11.26% a year earlier (+243 bps YoY), though it eased from 14.93% in Q4 FY26 (-124 bps QoQ). Net margin followed the same pattern: 8.52% versus 6.07% YoY, and roughly flat against 8.56% in Q4. By segment, Pharmaceuticals remained the larger profit contributor (revenue ₹469.49 Cr, segment PBIT ₹68.81 Cr), but Chemicals did the heavy lifting on margin recovery — segment PBIT nearly tripled YoY to ₹17.32 Cr from ₹5.91 Cr on revenue of ₹364.96 Cr, lifting the segment's PBIT margin to 4.7% from 2.1%. The 37% YoY revenue growth runs well ahead of the "mid-to-high teens" annual pace management guided on the Q4 FY26 call (22 May 2026), and the 13.69% OPM is closing in on, but still short of, the 14–14.5% FY27 margin band the company targeted then. No Q1-specific street estimate could be located; the closest available read (Univest) pegs FY27 full-year consensus PAT growth at 12–18% — Q1's +90% YoY pace runs well ahead of that trajectory, though a single quarter isn't directly comparable to a full-year estimate. Standalone and consolidated numbers tell nearly identical stories this quarter (PAT ₹64.48 Cr vs ₹64.40 Cr, a 0.12% gap), the difference owing entirely to the first-time, auditor-flagged-immaterial consolidation of UK subsidiary IOL Pharmaxis, which began operations in April 2026. The board approved the results alongside routine filings this week (BRSR report, FY26 annual report, 39th AGM notice for 2 September 2026); no new capex or corporate action accompanied the print. With OPM still 35–80 bps below the FY27 target band and Chemical segment margins recovering off a low base, the next one to two quarters should clarify whether this run-rate holds or whether Q1's step-up partly reflects a favorable base effect against a soft year-ago chemical pricing environment.

IOL Chemicals & Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report, which forms an integral part of the company's Integrated Annual Report, details the company's performance across environmental, social, and governance (ESG) parameters. Key disclosures include business activities contributing to turnover (Pharma Segment 60%, Chemical Segment 40%), products sold (APIs and Intermediates 59.66%, Specialty Chemicals 39.43%), employee details (3592 total employees), and market reach (23 national states, 70 international countries). The BRSR was prepared on a standalone basis and received reasonable assurance from Intertek India Private Limited.

IOL Chemicals & Pharmaceuticals Ltd has announced its 39th Annual General Meeting (AGM) will be held on Wednesday, September 2, 2026, at 11:30 a.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of standalone and consolidated audited financial statements for the financial year ended March 31, 2026, the re-appointment of Mr. Kushal Kumar Rana as a director, and the ratification of the Cost Auditor's remuneration for the financial year ending March 31, 2027. The AGM notice is part of the company's Integrated Annual Report for FY 2025-26, available on their website.

IOL Chemicals & Pharmaceuticals Ltd has submitted its Integrated Annual Report for the financial year 2025-26. The report includes the Notice for the 39th Annual General Meeting (AGM), scheduled for September 2, 2026, at 11:30 a.m. IST, to be conducted via Video Conferencing. The report is available electronically to members and on the company's website. It highlights the company's 'Guiding Compass Journey Forward' strategy, emphasizing consistent quality, diversification, disciplined execution, innovation, and sustainability. The report covers a legacy of forty years, mentioning 14 USFDA Drug Master Files and 21 EDQM Certificates of Suitability, and positions the company to advance API manufacturing in India's growing pharmaceutical sector.

IOL Chemicals & Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 10, 2026. The primary agenda item is to consider and approve the Un-audited Financial Results for the first quarter ended June 30, 2026. Concurrently, the company will manage its trading window closure, which began on July 1, 2026, and will reopen 48 hours after the financial results are publicly disclosed, expected on August 13, 2026, in compliance with SEBI regulations.

IOL Chemicals & Pharmaceuticals Ltd announced that the Centre for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved its API product, Clopidogrel Bisulfate. This approval, granted on July 14, 2026, is in addition to the company's existing Certificate of Suitability (CEP) for the same product. The NMPA approval is expected to significantly enhance the company's regulatory standing and expand its market access within China's pharmaceutical sector.